Literature DB >> 16794785

Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands.

M Tsuji1.   

Abstract

Natural killer T (NKT) cells have been shown by a number of studies to play a protective role against cancers, autoimmune diseases and infectious diseases. Several glycolipids and phospholipids derived from mammalian, bacterial, protozoan and plant species have recently been identified as natural ligands (antigens) for NKT cells. Some of these glycolipid/phospholipid ligands have now been crystallized in forms bound to CD1d molecules, and the tertiary structure of these complexes has finally been revealed. This review is intended to list natural NKT cell ligands identified to date, and discuss how their structures relate to their propensity to bind CD1d molecules and, as a consequence, stimulate NKT cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794785     DOI: 10.1007/s00018-006-6073-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  35 in total

Review 1.  Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors:  Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal:  Clin Immunol       Date:  2010-12-24       Impact factor: 3.969

2.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

3.  Synthesis of all stereoisomers of KRN7000, the CD1d-binding NKT cell ligand.

Authors:  Jeong-Ju Park; Ji Hyung Lee; Subhash C Ghosh; Gabriel Bricard; Manjunatha M Venkataswamy; Steven A Porcelli; Sung-Kee Chung
Journal:  Bioorg Med Chem Lett       Date:  2008-06-14       Impact factor: 2.823

4.  Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses.

Authors:  Rafael S Grajewski; Anna M Hansen; Rajeev K Agarwal; Mitchell Kronenberg; Stephane Sidobre; Shao Bo Su; Phyllis B Silver; Moriya Tsuji; Richard W Franck; Anne P Lawton; Chi-Chao Chan; Rachel R Caspi
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  The 3-Deoxy Analogue of α-GalCer: Disclosing the Role of the 4-Hydroxyl Group for CD1d-Mediated NKT Cell Activation.

Authors:  Dong Jae Baek; Jeong-Hwan Seo; Chaemin Lim; Jae Hyun Kim; Doo Hyun Chung; Won-Jea Cho; Chang-Yuil Kang; Sanghee Kim
Journal:  ACS Med Chem Lett       Date:  2011-05-16       Impact factor: 4.345

6.  Alpha-S-GalCer: synthesis and evaluation for iNKT cell stimulation.

Authors:  Marisa L Blauvelt; Maryam Khalili; Weonjoo Jaung; Janet Paulsen; Amy C Anderson; S Brian Wilson; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2008-11-01       Impact factor: 2.823

Review 7.  CD1 mediated T cell recognition of glycolipids.

Authors:  Dirk M Zajonc; Mitchell Kronenberg
Journal:  Curr Opin Struct Biol       Date:  2007-10-24       Impact factor: 6.809

Review 8.  Glycolipids as immunostimulating agents.

Authors:  Douglass Wu; Masakazu Fujio; Chi-Huey Wong
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

9.  A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer.

Authors:  John Schmieg; Guangli Yang; Richard W Franck; Moriya Tsuji
Journal:  J Biomed Biotechnol       Date:  2009-12-27

Review 10.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.